CL2021003530A1 - Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020. - Google Patents
Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.Info
- Publication number
- CL2021003530A1 CL2021003530A1 CL2021003530A CL2021003530A CL2021003530A1 CL 2021003530 A1 CL2021003530 A1 CL 2021003530A1 CL 2021003530 A CL2021003530 A CL 2021003530A CL 2021003530 A CL2021003530 A CL 2021003530A CL 2021003530 A1 CL2021003530 A1 CL 2021003530A1
- Authority
- CL
- Chile
- Prior art keywords
- application
- crystalline hydrate
- fluorobenzyl
- imidazo
- triazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente divulgación se relaciona con el hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente divulgación también provee composiciones farmacéuticamente aceptables que comprenden el hidrato cristalino 1 y métodos para usar dichas composiciones en el tratamiento de diversas afecciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862639846P | 2018-03-07 | 2018-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003530A1 true CL2021003530A1 (es) | 2022-08-19 |
Family
ID=65818696
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002284A CL2020002284A1 (es) | 2018-03-07 | 2020-09-03 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) |
CL2021000301A CL2021000301A1 (es) | 2018-03-07 | 2021-02-04 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020. |
CL2021003531A CL2021003531A1 (es) | 2018-03-07 | 2021-12-28 | Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020 |
CL2021003530A CL2021003530A1 (es) | 2018-03-07 | 2021-12-28 | Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020. |
CL2021003536A CL2021003536A1 (es) | 2018-03-07 | 2021-12-28 | Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002284A CL2020002284A1 (es) | 2018-03-07 | 2020-09-03 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc) |
CL2021000301A CL2021000301A1 (es) | 2018-03-07 | 2021-02-04 | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020. |
CL2021003531A CL2021003531A1 (es) | 2018-03-07 | 2021-12-28 | Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003536A CL2021003536A1 (es) | 2018-03-07 | 2021-12-28 | Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020 |
Country Status (20)
Country | Link |
---|---|
US (2) | US11466015B2 (es) |
EP (1) | EP3762389B1 (es) |
JP (1) | JP7423539B2 (es) |
KR (1) | KR20200128708A (es) |
CN (1) | CN111836812A (es) |
AU (1) | AU2019231724A1 (es) |
BR (1) | BR112020018212A2 (es) |
CA (1) | CA3092683A1 (es) |
CL (5) | CL2020002284A1 (es) |
CO (1) | CO2020012493A2 (es) |
CR (1) | CR20200458A (es) |
EA (1) | EA202092109A1 (es) |
IL (1) | IL276853A (es) |
MA (1) | MA54638A (es) |
MX (5) | MX2023004857A (es) |
PE (1) | PE20210124A1 (es) |
PH (1) | PH12020551394A1 (es) |
SG (1) | SG11202008641WA (es) |
TW (1) | TWI823903B (es) |
WO (1) | WO2019173551A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020014504A1 (en) * | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
WO2021195403A1 (en) * | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途 |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE69928260T2 (de) | 1998-07-08 | 2006-07-20 | Sanofi-Aventis Deutschland Gmbh | Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
KR20100059952A (ko) | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
BRPI1008793A2 (pt) | 2009-02-26 | 2016-03-08 | Merck Sharp & Dohme | composto, uso de um composto, e, composição farmacêutica |
EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
PE20130222A1 (es) | 2010-05-27 | 2013-03-14 | Merck Sharp & Dohme | Activadores de guanilato ciclasa soluble |
EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
CN104327107A (zh) | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
WO2016087342A1 (de) * | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung |
LT3507291T (lt) * | 2016-09-02 | 2021-09-10 | Cyclerion Therapeutics, Inc. | Kondensuoti bicikliniai sgc stimuliatoriai |
-
2019
- 2019-03-07 CA CA3092683A patent/CA3092683A1/en active Pending
- 2019-03-07 MX MX2023004857A patent/MX2023004857A/es unknown
- 2019-03-07 BR BR112020018212-5A patent/BR112020018212A2/pt unknown
- 2019-03-07 EP EP19712427.4A patent/EP3762389B1/en active Active
- 2019-03-07 US US16/976,430 patent/US11466015B2/en active Active
- 2019-03-07 AU AU2019231724A patent/AU2019231724A1/en active Pending
- 2019-03-07 MX MX2023004858A patent/MX2023004858A/es unknown
- 2019-03-07 MX MX2023004855A patent/MX2023004855A/es unknown
- 2019-03-07 WO PCT/US2019/021080 patent/WO2019173551A1/en unknown
- 2019-03-07 MX MX2020009183A patent/MX2020009183A/es unknown
- 2019-03-07 CR CR20200458A patent/CR20200458A/es unknown
- 2019-03-07 CN CN201980017657.XA patent/CN111836812A/zh active Pending
- 2019-03-07 KR KR1020207028170A patent/KR20200128708A/ko not_active Application Discontinuation
- 2019-03-07 MA MA054638A patent/MA54638A/fr unknown
- 2019-03-07 TW TW108107664A patent/TWI823903B/zh active
- 2019-03-07 PE PE2020001347A patent/PE20210124A1/es unknown
- 2019-03-07 EA EA202092109A patent/EA202092109A1/ru unknown
- 2019-03-07 SG SG11202008641WA patent/SG11202008641WA/en unknown
- 2019-03-07 MX MX2023004856A patent/MX2023004856A/es unknown
- 2019-03-07 JP JP2020546378A patent/JP7423539B2/ja active Active
-
2020
- 2020-08-20 IL IL276853A patent/IL276853A/en unknown
- 2020-09-03 CL CL2020002284A patent/CL2020002284A1/es unknown
- 2020-09-05 PH PH12020551394A patent/PH12020551394A1/en unknown
- 2020-10-06 CO CONC2020/0012493A patent/CO2020012493A2/es unknown
-
2021
- 2021-02-04 CL CL2021000301A patent/CL2021000301A1/es unknown
- 2021-12-28 CL CL2021003531A patent/CL2021003531A1/es unknown
- 2021-12-28 CL CL2021003530A patent/CL2021003530A1/es unknown
- 2021-12-28 CL CL2021003536A patent/CL2021003536A1/es unknown
-
2022
- 2022-09-28 US US17/954,713 patent/US20230095799A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003531A1 (es) | Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020 | |
MX2021007579A (es) | Estimuladores de guanilato ciclasa soluble (sgc) biciclicos fusionados. | |
AR113758A1 (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
PE20181802A1 (es) | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares | |
MX2007004264A (es) | Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares. | |
MY187131A (en) | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | |
MX2020008237A (es) | Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias. | |
PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
EA030735B9 (ru) | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc) | |
NZ607904A (en) | Substituted imidazopyridazines | |
EA201691862A2 (ru) | Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы | |
IL210071A0 (en) | Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists | |
UY31493A1 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico | |
PE20171104A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
WO2018089330A3 (en) | Sgc stimulators | |
MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
MX2021000683A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de trk. | |
MX2021008645A (es) | Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk). | |
MX2023008755A (es) | Cristales de sal. | |
PE20020581A1 (es) | Derivados de pirazolpiridinas sustituidos con piridimidina como estimuladores de la guanilato ciclasa | |
EP4095137A4 (en) | USE OF A PYRIDO[1,2-A]PYRIMIDINONE COMPOUND FOR THE TREATMENT OF LYMPHOMAS |